Search company, investor...

Kubota Pharmaceutical Holdings

Founded Year




Date of IPO


About Kubota Pharmaceutical Holdings

Kubota Pharmaceutical Holdings (TYO: 4596) identifies and develops therapeutics to treat ophthalmic disorders customers worldwide. It is based in Tokyo, Japan.

Headquarters Location

Kasumigaseki Tokyu Building 4F 3-7-1 Kasumigaseki, Chiyoda-ku

Tokyo, 100-0013,


+81 3 6550 8928

Missing: Kubota Pharmaceutical Holdings's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Kubota Pharmaceutical Holdings's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Kubota Pharmaceutical Holdings News

Kubota Pharmaceutical Group Launches Its Unique Kubota Glass Technology Aiming to Revolutionize Myopia Management

Feb 24, 2023

02/14 2022 02/24/2023 | 03:05pm EST Message : *Required fields Tokyo, Japan--(Newsfile Corp. - February 24, 2023) - Kubota Pharmaceutical Holdings  (JPX: 4596) and its subsidiary Kubota Vision Inc. (Kubota Pharmaceutical Group), an ophthalmic medical solutions company headquartered in Tokyo, launches its unique Kubota Glass technology , aiming to revolutionize myopia management. Based on the technology, the company introduced a wearable device called Kubota Glass illuminated spectacles. These glasses are designed to correct refractive errors and provide specially focused illumination to assist with image enhancement and ambient lighting. Furthermore, the unique design of Kubota Glass may help reduce the increase in eye growth associated with myopia. The company has launched Kubota Glass in Japan and further aims to launch it across the globe. Kubota Glass has completed medical device registration in the U.S. and Taiwan. A multitude of studies have shown that myopia is increasing worldwide, and half the population is projected to be myopic by 2050. Kubota Pharmaceutical Group recognizes this growing concern and seeks to address the myopia epidemic with its proprietary Kubota Glass technology. Myopia is caused by excessive eye growth, which has been shown to be associated with insufficient exposure to natural sunlight and outdoor time. As such, Kubota Glass designed its proprietary illumination system to mimic a natural outdoor lighting environment in order to help manage eye growth. The device provides this effect without disrupting the clarity of the wearer's central vision. According to the company, early clinical results in children showed that wearing Kubota Glass for only 1.5 to 2 hours per day was projected to slow myopia progression by 148% and eye growth by 139%, on average, versus values derived from published literature for age- and ethnicity-matched children over one year. This may mean that unlike some other devices designed to manage myopia on the market, Kubota Glass doesn't require the user to wear it all day. The technology has potential benefits in terms of managing myopia in children and adults alike. This may be good news for individuals who spend most of their time indoors and experience less natural light, since Kubota Glass seeks to replicate outdoor lighting. With multiple light stimuli in the periphery of the lens which actively project optimal lighting and focus the light onto the peripheral part of the retina, users receive specialized lighting to aid in managing their myopia. " Kubota Glass technology is the result of our continuous effort and research on how light can be utilized in a beneficial way to help manage myopia. Studies have shown that more outdoor light is better for managing changes associated with myopia, and we believe Kubota Glass has the potential to help manage and possibly prevent myopia in the near future. Our research team is working hard to achieve that goal," says Dr. Ryo Kubota, Representative Executive Officer, Chairman, President & CEO at Kubota Pharmaceutical Holdings. About Kubota Pharmaceutical Holdings Kubota Pharmaceutical Holdings Co., Ltd. is headquartered in Tokyo, Japan, and was listed on the Tokyo Stock Exchange (Tokyo: 4596) in 2016. The company is committed to translating innovation into a diverse portfolio of drugs and devices to preserve and restore the vision for millions of people worldwide. Media contact:

Kubota Pharmaceutical Holdings Frequently Asked Questions (FAQ)

  • When was Kubota Pharmaceutical Holdings founded?

    Kubota Pharmaceutical Holdings was founded in 2015.

  • Where is Kubota Pharmaceutical Holdings's headquarters?

    Kubota Pharmaceutical Holdings's headquarters is located at Kasumigaseki Tokyu Building 4F, Tokyo.

  • What is Kubota Pharmaceutical Holdings's latest funding round?

    Kubota Pharmaceutical Holdings's latest funding round is IPO.

  • Who are the investors of Kubota Pharmaceutical Holdings?

    Investors of Kubota Pharmaceutical Holdings include SMBC Venture Capital.

  • Who are Kubota Pharmaceutical Holdings's competitors?

    Competitors of Kubota Pharmaceutical Holdings include Reopia Optics.

Compare Kubota Pharmaceutical Holdings to Competitors


HOYA provides eyecare services. The company offers progressive lenses, occupational lenses, photochromic lenses, myopia control solutions, and more. It was founded in 1941 and is based in Amsterdam, Netherlands.

Reopia Optics

Reopia Optics develops eyeglasses that prevent children from nearsightedness. It is based in San Bruno, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.